CRISPR Therapeutics AG news

While the company shows strong revenue growth projections (+771.5% current year, +294.6% next year) and improving earnings estimates (+30.9% current year), it carries a Zacks Rank #3 (Hold) rating and trades at a significant premium valuation (F grade) relative to peers. The stock is expected to perform in line with the broader market, suggesting limited upside potential despite positive fundamentals.

CRISPR has achieved a breakthrough with FDA-approved Casgevy gene-editing therapy and expanded patient population, but faces significant headwinds including $581.6M net loss in FY2025, $345.9M negative free cash flow, heavy dependence on Vertex partnership, and substantial ongoing cash burn. High-risk, high-reward profile makes it suitable only for risk-tolerant investors.

Early-stage biotech with revolutionary CASGEVY gene therapy showing momentum and accelerating revenue, but currently unprofitable with $581.6M net loss and negative $345.9M free cash flow. High growth potential offset by substantial execution risk and dependence on Vertex partnership. Suitable only for risk-tolerant investors.

Strong Q2 earnings beat analyst expectations with 78% sequential sales growth for Casgevy, FDA pediatric label expansion approval, $10 million licensing deal, and significant net loss reduction. Stock gained nearly 19% in August on solid execution across portfolio and platform.

Company beat earnings and revenue estimates, narrowed losses significantly year-over-year, controlled costs effectively, and benefited from strong Casgevy sales growth through Vertex partnership. Upward estimate revisions of 10.46% and positive momentum score support positive sentiment, though Hold rating and poor Growth/Value scores temper enthusiasm.

The article highlights CRISPR's underrated CAR T-cell therapy development program alongside its approved Casgevy drug. The CAR T approach offers cost advantages through off-the-shelf donor cell treatments, and the market is projected to grow 30% annually through 2034. Cathie Wood's substantial $362 million investment signals confidence in the company's multiple growth catalysts.

Company has achieved groundbreaking first CRISPR-based product approval for sickle cell disease, has existing revenue ($3.5M), strong balance sheet metrics (current ratio 13.3, low debt-to-equity 0.2), and $2.4B in cash. Despite significant losses and customer concentration risks, the author recommends it as the better choice between the two options.

Listed as a key player in the competitive landscape with strong market positioning. The company benefits from the projected 11.4% CAGR market growth and increasing adoption of CRISPR platforms in drug development.

The article highlights strong analyst support (58% buy ratings with 437% upside), successful FDA approval of Casgevy, a robust pipeline with five additional therapies, and significant growth projections. The company's modest market cap relative to potential market opportunity and first major commercial success support a positive outlook, despite current early-stage revenue and speculative nature.

The acquisition of CTX611 represents a strategic expansion beyond gene editing into a large anticoagulant market worth billions annually. Even as a follower program, success could significantly boost the company's minimal current revenue of $1.4 million, making it a potentially transformative asset.

Company has first FDA-approved CRISPR therapy (CASGEVY), stronger balance sheet with $423.3M cash, 13.3x current ratio, lower debt-to-equity (0.2x), and is further along in commercialization. These factors position it as lower-risk with near-term revenue potential.

Company has FDA-approved product (Casgevy) with expected significant commercial growth, deeper pipeline with promising candidates like CTX310, stronger cash position ($2.4B), and lower risk profile compared to competitor. Recommended as the better investment choice.

Strong analyst price targets (average $82.55, some as high as $110) suggest significant upside potential. Multiple near-term catalysts including CTX611 clinical data and Casgevy expansion to pediatric patients. Proven platform with Casgevy approval and strong cash position ($2.4B) support bullish outlook, though execution risk remains.

Company has achieved regulatory approval for its first product (Casgevy), demonstrated early promising clinical data for zugo-cel in autoimmune diseases, and operates in a massive market opportunity ($223B by 2034). The article positions it as a potential next major growth theme.

The company has multiple near-term clinical catalysts in 2026 with potentially transformative pipeline candidates (CTX611, zugo-cel, CTX310) addressing large markets. Recent 12-month momentum and the first approved CRISPR medicine (Casgevy) demonstrate progress, though significant execution risk remains.

Strong cash position of $2 billion provides financial runway; Casgevy sales accelerating with $54 million in Q4 2025 alone; robust pipeline with five therapies in clinical trials targeting large markets (cardiovascular disease, cancers, autoimmune disorders); potential for gene-editing therapies to offer functional cures rather than just treatments.

The company has a promising pipeline with potentially transformative candidates (CTX310, CTX320) that could redefine cardiovascular treatment and address significant unmet medical needs. The one-time gene-editing approach represents a major innovation in the therapeutic area with a large addressable market (40 million people in the U.S. with high TG/LDL levels).

The company has promising technology and an approved therapy (Casgevy) with strong cash reserves ($1.8B), but faces significant challenges including massive net losses ($581.6M), minimal revenue ($3.5M), and dilutive equity offerings. The analyst views it as a speculative mid-cap opportunity with potential upside rather than a clear buy or sell.

Stock fell 12% on announcement of $350M convertible debt offering that could dilute existing shareholders. However, the article notes this decline may be an overreaction, as analysts maintain a bullish consensus price target of $81.21 (50% above current price) and the capital raise was likely anticipated by the market. The company's successful gene therapy approvals and five ongoing clinical trials support long-term potential despite near-term negative sentiment.

High upside potential from promising pipeline candidates (CTX310 for cholesterol treatment) but significant downside risk due to heavy reliance on single approved drug (Casgevy) with slow commercial adoption, consistent losses, and clinical execution risk.

Strong Q4 results with Casgevy revenue of $116M annually, patient initiations nearly tripling YoY to 147, expanding reimbursement coverage (~90% of eligible U.S. patients), and promising pipeline progress across multiple therapeutic areas. Stock up 8.81% reflects market confidence.

CTX340 targeting angiotensinogen received FDA IND clearance with Phase I trial initiated for refractory hypertension, representing progress in gene-editing approach to hypertension treatment.

CRISPR Therapeutics is developing CTX110, an investigational CAR T therapy in the emerging pipeline. The company is positioned to benefit from market expansion and innovation in next-generation therapies.

Casgevy revenue is accelerating (78% YoY growth in Q2), with analyst projections showing significant revenue expansion from $40M to $156M in 2027. The company is approaching a major inflection point as the treatment pipeline matures.

CRISPR showed exceptional revenue growth of 1043.8% year-over-year and improved EPS, but carries a Hold rating with an F VGM Score. The stock gained 8.5% over the past month, though valuation concerns and modest estimate revisions limit positive sentiment.

CRISPR partnered with Vertex to develop Casgevy, a gene-editing medicine approved for rare blood diseases with recent label expansion to younger patients. This partnership positions CRISPR favorably in the emerging gene-editing therapeutic space.

Stock has been stagnant since 2022 but revenue inflection is imminent with 500+ patients in treatment pipeline. Analysts expect $40M revenue this year and $160M+ next year, providing a near-term catalyst for stock appreciation.

Mentioned as a top holding in Ark Innovation ETF but not discussed in the article content.

Mentioned as a competitor in the gene-editing space. The article notes intensifying competition but does not provide specific analysis of CRISPR's prospects or performance.

Mentioned as partnership developer of CASGEVY (gene therapy), which provides Vertex with recent approval and runway. Partnership context is positive but article provides limited direct information about CRISPR's standalone prospects.

Leading player in CRISPR-based gene editing therapeutics with strong market positioning. The article highlights CRISPR technology dominance and the company's role in next-generation therapy development, supporting growth prospects in an expanding market.

Mentioned as a competitor to Prime Medicine in gene-editing technology with potential to develop safer or more effective treatments, representing competitive risk but not directly evaluated.

Mentioned as co-marketer of Casgevy with Vertex for gene editing therapy in sickle cell disease and beta-thalassemia. While this represents a growth opportunity, the article focuses primarily on Vertex's prospects rather than providing specific analysis of CRISPR's position or performance.

Mentioned as partner with Vertex Pharmaceuticals in developing Casgevy for blood disorders. Limited detail provided; mentioned only in context of Vertex's expansion success.

Highlighted as an early-stage biotech with innovative candidates that could deliver significant share appreciation. Recommended for aggressive investors willing to accept higher risk for growth potential.

Positive read-through from NTLA's CRISPR breakthrough; broader gene-editing cohort benefits from platform validation event.

Established pure play in gene editing with CASGEVY already generating $100M+ in revenue. Positive Phase 1 data for CTX310 cardiovascular candidate provides growth runway. Most commercially mature of the three candidates, though 24% short interest warrants cautious entry.

Company reported strong Phase 1 data for CTX310 showing significant reductions in cardiovascular risk markers (73% ANGPTL3, 55% triglycerides, 49% LDL cholesterol) with a single-dose approach, demonstrating therapeutic potential.

The article presents CRISPR Therapeutics as a 'blastoff-ready' biotech stock with proven technology (FDA-approved Casgevy), multi-billion-dollar revenue potential, and multiple clinical catalysts expected in 2026. The author recommends buying the stock and suggests investors will regret not purchasing it.